US Patent

US10555902 — Stable fingolimod dosage forms

Method of Use · Assigned to Handa Pharmaceuticals LLC · Expires 2036-01-19 · 10y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for preparing stable solid pharmaceutical dosage forms of fingolimod or its salts, conjugates, or complexes.

USPTO Abstract

The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrates in a patient's oral cavity.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3268 — fingolimod-lauryl-sulfate
U-3493 — fingolimod-lauryl-sulfate

Patent Metadata

Patent number
US10555902
Jurisdiction
US
Classification
Method of Use
Expires
2036-01-19
Drug substance claim
No
Drug product claim
No
Assignee
Handa Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.